This page provides a comprehensive overview of companies developing diagnostic technologies and imaging solutions for Alzheimer's disease (AD) and related neurodegenerative conditions. The diagnostic imaging landscape has evolved significantly with advances in PET tracers, blood-based biomarkers, and AI-powered image analysis[@alzheimers2024].
This page provides a comprehensive overview of companies developing diagnostic technologies and imaging solutions for Alzheimer's disease (AD) and related neurodegenerative conditions. The diagnostic imaging landscape has evolved significantly with advances in PET tracers, blood-based biomarkers, and AI-powered image analysis[@alzheimers2024].
The Alzheimer's diagnostic market encompasses several key technology areas:
[Life Molecular Imaging](/companies/life-molecular-imaging) is a German company specializing in PET tracers for neurodegenerative diseases. Key products include:
| Product | Target | Status |
|---------|--------|--------|
| Neuraceq® (Florbetaben F-18) | Beta-amyloid plaques | FDA approved (2014) |
| LMI 119 | Tau protein | Phase 2 |
| LMI 104 | Alpha-synuclein | Preclinical |
The company was acquired by Lantheus Holdings in 2024, strengthening its commercial capabilities[@lantheus2024].
Cerveau Technologies is developing next-generation PET tracers for tau pathology imaging in Alzheimer's disease and other tauopathies. Their lead program focuses on MK-6240, a high-affinity tau PET tracer.
| Tracer | Target | Development Stage |
|--------|--------|-------------------|
| MK-6240 | Tau neurofibrillary tangles | Phase 2/3 |
MK-6240 has demonstrated excellent properties for imaging tau pathology in AD patients and is being used in multiple therapeutic trials[@cerveau2024].
| Company | Focus Area | Key Products |
|---------|------------|--------------|
| AC Immune | Tau PET tracers | ACI-35.030 (vaccine), PET tracers in development |
| Roche | Amyloid and Tau | Gantenerumab (therapeutic), diagnostic tracers |
| Eisai | Amyloid PET | E2609 (elenbecestat), imaging biomarkers |
[Roche](/companies/roche) offers the Elecsys platform, one of the most widely deployed automated biomarker measurement systems in clinical practice. Key assays include:
Fujirebio, a Japanese in vitro diagnostics company, offers the Lumipulse G platform with comprehensive Alzheimer's biomarker panels:
Quanterix developed the Simoa (Single Molecule Array) technology, enabling ultra-sensitive biomarker detection with femtomolar sensitivity. The platform is widely used in research and pharmaceutical clinical trials.
| Assay | Application |
|-------|-------------|
| Simoa p-Tau181 | High-sensitivity plasma tau measurement |
| Simoa Aβ42/40 | Ultra-sensitive amyloid detection |
| Simoa NfL | Neurodegeneration marker |
[icometrix](/companies/icometrix) is a Belgian medical AI company specializing in quantitative brain MRI analysis. Their FDA-cleared and CE-marked products include:
brainomix develops AI-powered imaging analysis solutions for stroke and neurological conditions. Their platform provides:
| Company | Technology | Application |
|---------|------------|-------------|
| DeepMind (Google) | AI for MRI analysis | Brain age estimation, pathology detection |
| IXICO | AI imaging analytics | Clinical trial imaging endpoints |
| Radiology Partners | AI radiology platform | Large-scale imaging analysis |
| Segment | Market Size (2024) | Projected Growth |
|---------|-------------------|------------------|
| PET Imaging | $1.2B | 8% CAGR |
| Blood Biomarkers | $800M | 15% CAGR |
| AI Imaging Analytics | $400M | 20% CAGR |
Headquarters: Berlin, Germany Parent Company: Lantheus Holdings Founded: 2013 Focus: PET tracers for neurodegenerative diseases
Key products: Neuraceq® (florbetaben F-18), LMI 119 (tau), LMI 104 (alpha-synuclein)
Headquarters: Leuven, Belgium Founded: 2011 Focus: AI-powered MRI analysis
Key products: icobrain, icobrain AD, icobrain tau
Headquarters: Basel, Switzerland Focus: In vitro diagnostics, biomarker assays
Key products: Elecsys p-Tau181, Elecsys p-Tau217, Elecsys Aβ42/40